Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1.
Janusz JA, Klein-Tasman BP, Payne JM, Wolters PL, Thompson HL, Martin S, de Blank P, Ullrich N, Del Castillo A, Hussey M, Hardy KK, Haebich K, Rosser T, Toledo-Tamula MA, Walsh KS; REiNS International Collaboration. Janusz JA, et al. Among authors: thompson hl. Neurology. 2021 Aug 17;97(7 Suppl 1):S73-S80. doi: 10.1212/WNL.0000000000012422. Epub 2021 Jul 6. Neurology. 2021. PMID: 34230205 Free PMC article.
Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.
Walsh KS, Janusz J, Wolters PL, Martin S, Klein-Tasman BP, Toledo-Tamula MA, Thompson HL, Payne JM, Hardy KK, de Blank P, Semerjian C, Gray LS, Solomon SE, Ullrich N; REiNS International Collaboration. Walsh KS, et al. Among authors: thompson hl. Neurology. 2016 Aug 16;87(7 Suppl 1):S21-30. doi: 10.1212/WNL.0000000000002928. Neurology. 2016. PMID: 27527646 Free PMC article.
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO; Whole Body MRI Committee for the REiNS International Collaboration; REiNS International Collaboration Members 2016. Ahlawat S, et al. Neurology. 2016 Aug 16;87(7 Suppl 1):S31-9. doi: 10.1212/WNL.0000000000002929. Neurology. 2016. PMID: 27527647 Free PMC article.
Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.
Wolters PL, Martin S, Merker VL, Tonsgard JH, Solomon SE, Baldwin A, Bergner AL, Walsh K, Thompson HL, Gardner KL, Hingtgen CM, Schorry E, Dudley WN, Franklin B; REiNS International Collaboration. Wolters PL, et al. Among authors: thompson hl. Neurology. 2016 Aug 16;87(7 Suppl 1):S4-S12. doi: 10.1212/WNL.0000000000002927. Neurology. 2016. PMID: 27527648 Free PMC article.
Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR; REiNS International Collaboration. Hanemann CO, et al. Neurology. 2016 Aug 16;87(7 Suppl 1):S40-8. doi: 10.1212/WNL.0000000000002932. Neurology. 2016. PMID: 27527649 Free PMC article.
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
Wolters PL, Vranceanu AM, Thompson HL, Martin S, Merker VL, Baldwin A, Barnett C, Koetsier KS, Hingtgen CM, Funes CJ, Tonsgard JH, Schorry EK, Allen T, Smith T, Franklin B, Reeve S; REiNS International Collaboration. Wolters PL, et al. Among authors: thompson hl. Neurology. 2021 Aug 17;97(7 Suppl 1):S50-S63. doi: 10.1212/WNL.0000000000012421. Epub 2021 Jul 6. Neurology. 2021. PMID: 34230198 Free PMC article.
Recommendations for Measurement of Attention Outcomes in Preschoolers With Neurofibromatosis.
Klein-Tasman BP, Lee K, Thompson HL, Janusz J, Payne JM, Pardej S, de Blank P, Kennedy T, Janke KM, Castillo AD, Walsh KS; REiNS International Collaboration. Klein-Tasman BP, et al. Among authors: thompson hl. Neurology. 2021 Aug 17;97(7 Suppl 1):S81-S90. doi: 10.1212/WNL.0000000000012423. Epub 2021 Jul 6. Neurology. 2021. PMID: 34230206
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
Fertitta L, Bergqvist C, Sarin KY, Plotkin SR, Moertel C, Petersen AK, Cannon A, Berman Y, Pichard DC, Röhl C, Lessing A, Brizion B, Peiffer B, Ravaud P, Tran VT, Armand ML, Moryousef S, Ferkal S, Jannic A, Ezzedine K, Wolkenstein P; Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) international collaboration. Fertitta L, et al. Br J Dermatol. 2024 Jan 23;190(2):216-225. doi: 10.1093/bjd/ljad397. Br J Dermatol. 2024. PMID: 37877514
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
Merker VL, Thompson HL, Wolters PL, Buono FD, Hingtgen CM, Rosser T, Barton B, Barnett C, Smith T, Haberkamp D, McManus ML, Baldwin A, Moss IP, Röhl C, Martin S. Merker VL, et al. Among authors: thompson hl. Clin Trials. 2024 Feb;21(1):6-17. doi: 10.1177/17407745231205577. Epub 2023 Dec 23. Clin Trials. 2024. PMID: 38140900 Free PMC article.
106 results